Olainfarm
Olpha (formerly Olainfarm) is a Latvian pharmaceutical manufacturer producing finished drug forms, active pharmaceutical ingredients, and intermediates across ten therapeutic areas, serving 60+ markets through 850+ specialists and a portfolio of B2B services including contract manufacturing and licensing.
- Company typePublic
- Founded1972
- HeadquartersOlaine, Latvia
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Olainfarm does
Olainfarm, now operating under the Olpha brand, is a publicly listed Latvian pharmaceutical manufacturer headquartered in Olaine. Founded in 1972, the company employs 850+ specialists and operates through five group companies. It produces finished drug forms, active pharmaceutical substances (APIs), and intermediates, with a portfolio of more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates spanning ten therapeutic areas: urology, hematology, cardiology, allergology, neurology, oncology, pain and inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, and pulmonology.
The company distributes finished products through direct pharmaceutical channels in more than 60 markets across the Baltic States, Eastern Europe, Central Asia, the Caucasus, the Balkans, and Mongolia. Alongside its captive product portfolio, Olpha runs a portfolio of business-to-business services including pharmaceutical contract manufacturing, pharmaceutical co-development, pharmaceutical out-licensing, dietary supplement manufacturing, and product lifecycle management, targeting pharmaceutical companies as partners. It also operates research and development functions for both APIs/intermediates and finished dosage forms, including product development and registration support.
The firm is listed on the Nasdaq Riga stock exchange under the ticker OLF (legal name AS Olpha). Recent strategic activity includes a 5.84 million EUR investment to expand production capacity at the Olaine site, an announced pivot into drug development services exports, and a 2024 corporate rebranding from Olainfarm to Olpha. The management board is chaired by Valerijs Maligins, with functional directors leading manufacturing, quality management, technical, product development, and administration. Historical M&A activity between 2011 and 2016 added pharmacy, diagnostics (Klinika DiaMed), medical devices (Tonus Elast), and cosmetics (Kiwi Cosmetics) assets to the group.
Olainfarm firmographics
Firmographics- Name
- Olainfarm
- Legal name
- Akciju sabiedrība "Olpha"
- Website
- https://olainfarm.lv
- Company type
- Public
- Founded year
- 1972
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Olpha (formerly Olainfarm) is a Latvian pharmaceutical manufacturer producing finished drug forms, active pharmaceutical ingredients, and intermediates across ten therapeutic areas, serving 60+ markets through 850+ specialists and a portfolio of B2B services including contract manufacturing and licensing.
- Ownership category
- akta.pro rank
Olainfarm industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Olainfarm is headquartered
LocationHeadquarters
- HQ city
- Olaine
- HQ country
- Latvia
- HQ region
- Europe
Offices1 record
Markets served
Olainfarm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Manufacturing and Sales: Manufacturing and sale of pharmaceutical products including finished dosage forms, active pharmaceutical ingredients, and intermediates across 10 therapeutic areas
- Contract Manufacturing: Custom manufacturing services for pharmaceutical partners, producing finished dosage forms, APIs, and intermediates
- Pharmaceutical Co-development: Joint development partnerships for pharmaceutical products and formulations
- Pharmaceutical Licensing: Licensing arrangements for pharmaceutical products and formulations
- Nutritional Supplement Manufacturing: Production of dietary supplements for business partners
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Olainfarm product offering
Product offeringCore offering
Olainfarm (brand: Olpha) manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. In addition to its branded pharmaceutical portfolio of 60+ drug forms, the company offers contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, and dietary supplement manufacturing services to business partners across 60+ markets.
Product overview
Olpha (formerly Olainfarm) is a leading pharmaceutical manufacturer in the Baltic region with more than 50 years of experience. The company offers a unified portfolio of over 60 drug forms, 25 active pharmaceutical substances, and 20+ intermediates across 10 therapeutic groups (Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, Pulmonology). Beyond its core pharmaceutical products, Olpha provides comprehensive business services including contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, dietary supplement manufacturing, and product management. The company operates with over 850 specialists and serves 60+ markets through 5 group companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Products Portfolio Olpha's core pharmaceutical product portfolio comprising more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates for family health. Products cover 10 therapeutic groups including Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, and Pulmonology.
- Contract Manufacturing Pharmaceutical contract manufacturing services for finished drug forms, active pharmaceutical substances, and intermediates, leveraging over 850 specialists and more than 50 years of experience. Designed for pharmaceutical business partners seeking reliable manufacturing partners.
- Pharmaceutical Co-development Collaborative pharmaceutical development services for new drug formulations and products, enabling joint development partnerships with pharmaceutical companies.
- Pharmaceutical Licensing Out-licensing services for pharmaceutical products to enable market expansion for business partners across multiple geographies.
- Dietary Supplement Manufacturing Manufacturing services for nutritional and dietary supplements for business partners.
- Product Management Comprehensive product lifecycle management services for pharmaceutical products offered to business partners.
- Active Pharmaceutical Substances and Intermediates R&D Research and development services for active pharmaceutical substances and intermediates offered to business partners.
- Finished Drug Form R&D Research and development services for finished dosage forms offered to business partners.
Companies that use Olainfarm
Customer profileSegments3 records
Ideal customer profiles3 records
Olainfarm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Olainfarm partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights5 records
Olainfarm competitors and assessment
Company assessmentDirect peers
- Polpharma: One of the largest Polish pharmaceutical manufacturers producing generics, APIs, and finished dosage forms. Comparable scale, vertical integration across the value chain, and focus on Central and Eastern European markets with growing international distribution.
- Gedeon Richter: Hungarian-headquartered pharmaceutical company with strong generics, APIs, and branded pharma operations across CEE and CIS regions. Comparable vertical integration (APIs through finished forms), regional geographic footprint, and established presence in markets Olpha serves.
- Grindeks: Latvian-headquartered pharmaceutical manufacturer producing finished dosage forms, APIs, and generics across multiple therapeutic areas. Closest comparable peer given shared Latvian/Baltic origin, similar vertical integration profile, and overlapping generic pharma business model.
- KRKA: Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished dose production across Central and Eastern European markets. Highly comparable business model, geographic focus on CEE/CIS, and generic product portfolio spanning similar therapeutic categories.
- STADA Arzneimittel: German-based European generics and consumer healthcare company with extensive generic pharmaceutical portfolio and strong presence in CEE/CIS markets. Comparable multi-market distribution model and generic finished dosage form focus.
- Zentiva: European generics-focused pharmaceutical manufacturer headquartered in Prague, serving CEE and Western European markets with a broad generic and OTC portfolio. Comparable product portfolio breadth, therapeutic diversification, and B2B partnership offerings.
Regional players
- Darnitsa: Ukrainian pharmaceutical manufacturer producing generics and finished dosage forms primarily for the Ukrainian and CIS markets. Comparable vertical integration and therapeutic breadth, but focused on a different (CIS-centric) geography than Olpha's broader multi-market presence.
- Balkan Pharmaceuticals: Moldovan-based pharmaceutical manufacturer producing generics, APIs, and finished dosage forms for Eastern European and CIS markets. Comparable product category and manufacturing scope, with regional focus on similar territories to Olpha's CIS distribution.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with massive global API and finished dose capacity. Competes with Olpha in generic categories across all therapeutic areas and in the same Eastern European markets, but at substantially larger scale and broader portfolio scope.
- Sandoz (Novartis): Global generics-focused division of Novartis, one of the largest generic and biosimilar manufacturers worldwide. Competes across Olpha's therapeutic categories and geographies, with substantially greater scale, R&D budget, and regulatory footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Olainfarm social profiles
Digital presenceOlainfarm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Olainfarm leadership team
Management profileNumber of profiles
Profiles6 records
Olainfarm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Olainfarm M&A and investment
M&A and investmentM&A4 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Olainfarm
What does Olainfarm do?
Olainfarm (brand: Olpha) manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. In addition to its branded pharmaceutical portfolio of 60+ drug forms, the company offers contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, and dietary supplement manufacturing services to business partners across 60+ markets.
Is Olainfarm a public or private company?
Olainfarm is a public company. It is classified as public and is currently operating.
When was Olainfarm founded?
Olainfarm was founded in 1972. It employs 501 to 1,000 people.
Where is Olainfarm based?
Olainfarm is headquartered in Olaine, Latvia, in the Europe region.
How does Olainfarm make money?
Five revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are contract Manufacturing, pharmaceutical Co-development, pharmaceutical Licensing and nutritional Supplement Manufacturing.
Who are Olainfarm's main competitors?
Direct peers on record are Polpharma, Gedeon Richter, Grindeks, KRKA, STADA Arzneimittel and Zentiva. Regional players are Darnitsa and Balkan Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis).
Does Olainfarm have an API?
No public API is recorded for Olainfarm.
What industry is Olainfarm in?
Olainfarm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.